Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • Her2+ • NCI-CCC Breast Tumor Board Question
In which cases would you use adjuvant abemaciclib for a patient with extensive residual disease that is triple-positive (ER+PR+HER2+) following neoadjuvant TCHP?
Patient is ypT2N1
Answer from: Medical Oncologist at Community Practice
There is no evidence that adjuvant abemaciclib benefits the HR+ HER2+ setting. The biology between HR+ HER+ and HR- HER2+ is quite different.
Sign in or Register to read more